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Many good causes are paid
effectively from the interest on a
large sum of money endowed by
the original benefactor. This is true
for a wide range of prizes including
the Nobel prizes, and for a number
of agencies funding scientific
research, including the London-
based Wellcome Trust. With the
ongoing crisis of the stockmarkets,
some of these agencies, including
the Wellcome Trust, may be forced
to scale down their expenses.
Possible budget cuts at the
Wellcome Trust could be a serious
blow to life science research in the
UK and further afield, because the
trust is one of the largest
biomedical charities in the world.
Its mission is ‘to foster and
promote research with the aim of
improving human and animal
health’, and it has invested billions
in science, ranging from personal
career development grants
through to infrastructure
investments beyond 100 million
pounds, including the Wellcome
Trust Sanger Institute at Hinxton
near Cambridge, which
sequenced around 30% of the
human genome, and the Diamond
synchrotron project, which will
provide the UK with a new third
generation synchrotron based at
the Rutherford Appleton
Laboratory, near Oxford, and
replaces the old synchrotron at
Daresbury, Cheshire.
Like the company known as the
Wellcome Foundation, the
Wellcome Trust arose from the
legacy of the entrepreneur Henry
Wellcome (1853–1936). Essentially,
Wellcome merged several
companies he was involved with
into the Wellcome Foundation, and
arranged for his shares to be held
by the Wellcome Trust after his
death. After maintaining the link
with the company for nearly six
decades, the trust diversified its
assets in the 1990s and eventually
sold the company to Glaxo plc.,
keeping its wealth in a diverse
portfolio of shares.
Until the turn of the century, this
financial policy appeared to be
rewarded, as the trust continued to
grow. But the general economic
crisis basically spanning from the
dotcom crash to this day reduced
the current value of Henry
Wellcome’s endowment by a few
billion pounds from its peak of
nearly £15 billion to £9.3 billion in
September 2002. A Wellcome Trust
spokesperson said: “In common
with other charitable foundations,
our asset base has fallen over the
last three years as a result of falling
equity markets. Despite the
continuing uncertainty in the
immediate future, our prudent
spending policy means that this
will not have any effect on our
existing grant liabilities. However,
we are reviewing our future
spending plans over the coming
months and expect to conclude
this review later this year.”
No precise date for completion
of the expenditure plan, let alone
details of its content, are available
so far. It is expected to be
finished some time during this
summer, by which time the new
director of the charity, Professor
Mark Walport, will have taken up
office. Walport, currently head of
medicine at London’s Imperial
College, was unavailable for
comment prior to the beginning of
his directorship in June.
His predecessor, Mike Dexter,
who stepped down in March at
the end of the scheduled 5-year
tenure at the helm, used press
interviews to hint darkly that the
current situation, where the trust
invests more in UK biomedical
sciences than the corresponding
government body, the Medical
Research Council (MRC), might
turn out to be unsustainable.
While the Wellcome Trust also
deals with personal fellowships
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and project grants much like the
research councils and other
funding agencies around the
world, it has in recent years made
headlines by investing record
sums in infrastructure projects. In
the Joint Infrastructure Fund, the
grants given by the trust in
partnership with the UK
government and its research
councils are often used as a lever
to make government money
available. For instance, the trust
might approach the government
with the plan to invest significant
funds into a major building project
on condition that the government
matches the amount. Examples of
infrastructure projects include the
Diamond synchrotron and the
Sanger Institute.
With the current reduction of its
assets on the one hand, and a UK
government that has provided
science with satisfactory budget
increases over the last few years,
the trust — with its new director
and new finance plan — may
want to reconsider whether it
really has to be a bigger spender
than the government. It may
decide to leave the replacement
of ageing infrastructure at UK
universities in the hands of the
government, and focus on driving
forwards the most promising new
research projects. After all, its
mission is about research and
health, not about UK universities.
Unlike government agencies, the
trust is free to place its money
wherever it considers it most
efficient in terms of research that
saves and improves lives. Seeing
that many more and younger lives
can be saved by curing malaria
than by treating prostate cancer,
there might, for instance, be a
case for investing more of it in the
third world. If the trust decides to
place its funding differently from
the way it has done in recent
years, that might result in a
considerable shake-up to be felt
far and wide.
Weblinks: www.wellcome.ac.uk
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Britain’s researchers have been
doing quite well from government
funds for science projects in
recent years compared with many
other countries. But such funds
address only half the issue for
university researchers because
their institution must also stump
up funds and this arm of the
system has been seriously under
pressure. Therefore the
government has been trying to
use a mechanism to reward the
best research departments with
the highest share of the funding
cake. But the latest efforts to
boost further the funding for the
very best departments appear to
have backfired, as researchers
show increasing concern about
the manner in which those
departments will be identified.
In the 1990s a massive peer-
review process was announced —
the Research Assessment Exercise
(RAE) — which attempted to rank
on a scale of 1 to 5* the quality of
research being carried out in
universities, department by
department. The result, announced
in 1996, was then used to
determine the allocation of funds
for research by the main university
funding bodies. Funds were
skewed towards the higher-ranking
departments. The results of a new
assessment in 2001 saw a further
concentration of funds to the best
performing departments.
But included in the
government’s white paper on
education earlier this year was a
wish to concentrate funds further
on the very highest quality
departments ahead of the next
planned RAE in 2008. The Higher
Education Funding Council for
England (HEFCE) responded with
the proposal of labelling all
departments that received the 5*
ranking in the past two
assessments with a 5** score that
should win higher funding.
Consultation was promised on
how departments within this
group can be identified for the
highest status in future annual
funding rounds.
But the prospect that the
HEFCE can shortcut the massive
review process involved in the
RAE has caused deep unease.
HEFCE has announced that it is
bringing the next RAE forward by
one year to 2007, to fit better with
government spending plans, but
many researchers believe it is to
shorten the lifespan of the new 5**
departments before full peer
review can take place.
Half of the 30 panel chairs that
oversaw the most recent RAE
have threatened to withdraw from
helping HEFCE identify top
departments in a letter published
by the Times Higher Education
Supplement this month. They say
the principles of openness,
transparency and peer review
created by the funding councils
have ‘been completely
undermined’.
The House of Commons’
education select committee chair,
Barry Sheerman, which is
preparing a report on the
government’s white paper, said
about the new research ranking: “I
think it is a bit of a leap in the dark
and perhaps a case of not
thinking through the changes in
research funding and the effects
on institutions.”
The Royal Society, Britain’s
science academy, has gone
further in its response and has
recommended the scrapping of
the RAE altogether. It called on
the government to ‘get rid of the
rigid research rating system and
increase academic salaries to
boost morale and keep staff in the
British university system’.
“Potentially Nobel-prize winning
research could well start in lower-
rated institutions because it is
individuals and groups that
undertake research, not
departments or institutions,” said
Royal Society vice-president,
John Enderby.
The government may need to
look again if its goodwill towards
research is to reap the benefits it
desires.
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